Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. APGE
5. MU
6. GOOGL
7. DFTX
8. KR
9. MSTR
10. HOOD

Go back to Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial

Raymond James Reiterates Outperform Rating on Regeneron Pharma (REGN)

April 22, 2026 2:56 PM EDT

Raymond James analyst Chris Raymond reiterated an Outperform rating and $910.00 price target on Regeneron Pharma (NASDAQ: REGN).

The analyst comments "Remain Outperform rated on REGN shares following the companys Regeneron Roundtable investor event this morning on the C5 complement program. Recall REGN is developing two complementary treatments that target complement factor... More